Myelodysplastic syndrome

50 trials 24 recruiting MedDRA PT
50 Registered trials
24 Recruiting
37 Unique sponsors
31 Unique IMPs
38 Commercial trials
Drug classes (ATC)
— ATC code not specified 37
L Oncology (ATC L) 14
Mechanism of action (INN-stem analysis)
Unknown / small molecule 18 substances
Antimetabolite 4 substances
Kinase inhibitor 4 substances
BCL-2 inhibitor 2 substances
Monoclonal antibody (immune) 1 substance
Receptor fusion protein 1 substance
Alkylating agent 1 substance
Phase III: 10 Phase II: 13 Phase I/II: 3 Phase IV: 1 Phase I: 11 Phase I (Other): 8 Phase I (First in Human): 5

Filter these 50 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 50 trials

Phase III

10 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    AZACITIDINE; VENETOCLAX
    2023-507153-16-00 9 countries 2020 n=186
    Ended
  • Ascentage Pharma Group Inc. Commercial
    AZACITIDINE; LISAFTOCLAX
    2024-517247-31-00 13 countries 2025 n=377
    Recruiting
  • Institut De Recherches Internationales Servier IRIS Commercial
    AZACITIDINE; IVOSIDENIB
    2023-510155-37-00 5 countries 2025 n=26
    Recruiting
  • Syros Pharmaceuticals Inc. Commercial
    AZACITIDINE; TAMIBAROTENE
    2023-510361-97-00 9 countries n=417 Orphan
    Ended
  • Taiho Oncology Inc. Commercial
    AZACITIDINE; AZACITIDINE, CEDAZURIDINE
    2024-515098-93-00 7 countries 2025 n=588
    Recruiting
  • Takeda Development Center Americas Inc. Commercial
    ELRITERCEPT
    2024-516009-22-00 11 countries 2025 n=82
    Recruiting
  • Takeda Development Center Americas Inc. Commercial
    ELRITERCEPT
    2025-523544-12-00 14 countries n=112
    Pending
  • Assistance Publique Hopitaux De Paris Academic
    ANTI-T LYMPHOCYTE IMMUNOGLOBULIN FOR HUMAN USE, RABBIT; RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN
    2023-504555-27-00 1 country 2023 n=324
    Recruiting
  • Fondazione Gimema Franco Mandelli Onlus Academic
    AZACITIDINE
    2023-510515-19-00 1 country 2020 n=274
    Recruiting
  • Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting Academic
    ENASIDENIB MESILATE; IVOSIDENIB
    2022-502832-37-00 12 countries 2019 n=852 Orphan
    Ended

Phase II

13 trials
  • Agios Pharmaceuticals Inc. Commercial
    AG-946; AG-946 PHOSPHATE
    2022-500609-42-00 8 countries 2023 n=78
    Recruiting
  • Glaxosmithkline Research & Development Limited Commercial
    MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE
    2024-519928-24-00 5 countries 2025 n=56 Orphan
    Recruiting
  • Novartis Pharma AG Commercial
    SABATOLIMAB
    2024-515281-14-00 6 countries 2023 n=18
    Ended
  • Ryvu Therapeutics S.A. Commercial
    7,8-DIBROMO-5,6-DIHYDRO-9-METHYL-2-(1-PIPERAZINYL)-4H-IMIDAZO[4,5,1-IJ]QUINOLINE HYDROCHLORIDE
    2023-505910-10-00 4 countries 2024 n=174
    Ended
  • Ryvu Therapeutics S.A. Commercial
    7,8-DIBROMO-5,6-DIHYDRO-9-METHYL-2-(1-PIPERAZINYL)-4H-IMIDAZO[4,5,1-IJ]QUINOLINE HYDROCHLORIDE; RUXOLITINIB
    2025-521673-14-00 4 countries 2025 n=29
    Recruiting
  • Taiho Oncology Inc. Commercial
    DECITABINE, CEDAZURIDINE
    2024-516293-29-01 8 countries 2022 n=100
    Ended
  • Takeda Development Center Americas Inc. Commercial
    ELRITERCEPT
    2023-507469-24-00 4 countries 2022 n=56
    Ended
  • Groupe Francophone Des Myelodysplasies Academic
    MOMELOTINIB DIHYDROCHLORIDE MONOHYDRATE
    2024-519779-24-00 1 country 2025 n=57
    Recruiting
  • Haemato Oncology Foundation For Adults Netherlands Academic
    DECITABINE; MIDOSTAURIN
    2023-503829-18-00 2 countries 2019 n=139 Orphan
    Ended
  • Institut Paoli Calmettes Academic
    BUSULFAN; FLUDARABINE PHOSPHATE; RABBIT ANTI-HUMAN THYMOCYTE IMMUNOGLOBULIN
    2024-516435-27-00 1 country 2024 n=177
    Ended
  • Rigshospitalet Academic
    IMP not specified
    2024-518436-37-01 1 country 2021 n=70
    Recruiting
  • Technische Universitat Dresden Academic
    IMP not specified
    2023-507879-21-00 1 country 2026 n=220
    Recruiting
  • Universitaetsklinikum Tuebingen AöR Academic
    FLUDARABINE PHOSPHATE PH. EUR.; TREOSULFAN; VENETOCLAX
    2025-521372-62-00 1 country 2026 n=27
    Recruiting

Phase I/II

3 trials
  • Alx Oncology Inc. Commercial
    ALX148
    2024-513993-23-00 1 country 2022 n=3
    Ended
  • Aop Orphan Pharmaceuticals GmbH Commercial
    LB-208
    2025-523396-38-00 1 country n=60
    Pending
  • Cellcentric Limited Commercial
    INOBRODIB
    2024-519498-20-00 1 country 2025 n=16
    Recruiting

Phase IV

1 trial
  • Medizinische Hochschule Hannover Academic
    IMP not specified
    2024-512503-39-00 3 countries 2025 n=289
    Recruiting

Phase I

11 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    IMP not specified
    2023-507154-32-00 2 countries 2017 n=22
    Ended
  • Auron Therapeutics Inc. Commercial
    IMP not specified
    2025-521394-13-00 1 country n=10
    Pending
  • Bristol-Myers Squibb Services Unlimited Company Commercial
    IMP not specified
    2024-519537-29-00 2 countries 2026 n=35
    Recruiting
  • Byondis B.V. Commercial
    IMP not specified
    2023-507781-13-00 3 countries 2024 n=33
    Ended
  • Celgene Corp. Commercial
    IMP not specified
    2023-503869-34-00 1 country 2022 n=48
    Ended
  • Janssen - Cilag International Commercial
    IMP not specified
    2024-513199-16-00 1 country 2025 n=20
    Recruiting
  • Janssen - Cilag International Commercial
    IMP not specified
    2024-513918-35-00 1 country 2020 n=1
    Ended
  • Janssen - Cilag International Commercial
    IMP not specified
    2024-514341-10-00 2 countries 2025 n=107
    Recruiting
  • LAVA Therapeutics N.V. Commercial
    IMP not specified
    2024-518831-12-00 1 country 2025 n=20
    Ended
  • Schrodinger Inc. Commercial
    IMP not specified
    2023-507321-42-00 2 countries 2024 n=53
    Ended
  • Seagen Inc. Commercial
    IMP not specified
    2023-506945-42-00 1 country 2022 n=8
    Recruiting

Phase I (Other)

8 trials
  • Celgene Corp. Commercial
    IMP not specified
    2023-506117-22-00 5 countries 2022 n=153
    Ended
  • Hutchmed Ltd. Commercial
    IMP not specified
    2024-516369-36-00 1 country 2021 n=37
    Ended
  • Incyte Corp. Commercial
    IMP not specified
    2023-506145-38-00 3 countries 2021 n=44
    Recruiting
  • Taiho Oncology Inc. Commercial
    IMP not specified
    2024-516291-16-00 5 countries 2021 n=46
    Recruiting
  • Taiho Oncology Inc. Commercial
    IMP not specified
    2024-516292-33-00 5 countries 2021 n=50
    Ended
  • Taiho Oncology Inc. Commercial
    DECITABINE; DECITABINE, CEDAZURIDINE
    2024-516296-32-00 3 countries 2021 n=24
    Ended
  • Institut Paoli Calmettes Academic
    IMP not specified
    2024-515737-14-00 1 country 2024 n=29
    Recruiting
  • Celgene Corp. Academic
    IMP not specified
    2023-506117-22-00 5 countries 2022 n=153
    Ended

Phase I (First in Human)

5 trials
  • AstraZeneca AB Commercial
    AZD3632
    2025-521299-76-00 3 countries 2025 n=17
    Recruiting
  • Ellipses Pharma Limited Commercial
    AZACITIDINE; EP0042; VENETOCLAX
    2024-514588-24-00 1 country 2021 n=13
    Halted
  • Molecular Partners AG Commercial
    ANTIBODY MIMETIC PROTEIN BINDING TO T CELLS CD3, TUMOR-ASSOCIATED ANTIGENS CD70, CD33, CD123, AND HUMAN SERUM ALBUMIN; AZACITIDINE; VENETOCLAX
    2023-505259-39-00 3 countries 2023 n=221
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    SAR-443579
    2023-508357-58-00 2 countries 2022 n=57
    Ended
  • Medizinische Hochschule Hannover Academic
    IVOSIDENIB; MOLIDUSTAT SODIUM
    2024-514051-15-00 1 country 2023 n=27
    Halted
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Taiho Oncology Inc. Commercial 5 Phase I (Other), Phase II, Phase III 2
Celgene Corp. Commercial 3 Phase I, Phase I (Other) 0
Janssen - Cilag International Commercial 3 Phase I 2
Takeda Development Center Americas Inc. Commercial 3 Phase II, Phase III 1
AbbVie Deutschland GmbH & Co. KG Commercial 2 Phase I, Phase III 0
Ryvu Therapeutics S.A. Commercial 2 Phase II 1
Institut Paoli Calmettes Academic 2 Phase I (Other), Phase II 1
Medizinische Hochschule Hannover Academic 2 Phase IV, Phase I (First in Human) 1
Auron Therapeutics Inc. Commercial 1 Phase I 0
Bristol-Myers Squibb Services Unlimited Company Commercial 1 Phase I 1
Byondis B.V. Commercial 1 Phase I 0
LAVA Therapeutics N.V. Commercial 1 Phase I 0
Schrodinger Inc. Commercial 1 Phase I 0
Seagen Inc. Commercial 1 Phase I 1
Hutchmed Ltd. Commercial 1 Phase I (Other) 0
Incyte Corp. Commercial 1 Phase I (Other) 1
Agios Pharmaceuticals Inc. Commercial 1 Phase II 1
Glaxosmithkline Research & Development Limited Commercial 1 Phase II 1
Novartis Pharma AG Commercial 1 Phase II 0
Ascentage Pharma Group Inc. Commercial 1 Phase III 1
New trials by year
2019
2
2020
3
2021
7
2022
8
2023
5
2024
5
2025
13
2026
3
← All indication landscapes